<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN" "http://www.w3.org/TR/REC-html40/loose.dtd">
<html><body><html><body><section class="summaryOfFindings"><div class="section-header section-collapse-header" id="CD012744-sec-0036" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"><div class="section-header" id="CD012744-sec-0036"></div> <div class="table" id="CD012744-tbl-0001"> <a href="#0" class="open-table-viewer open-in-figure-viewer">Open in table viewer</a><div class="table-heading">
<span class="table-label">Summary of findings for the main comparison.</span>Â <span class="table-title">Pilocarpine compared to no treatment/placebo for preventing salivary gland dysfunction following radiotherapy</span>
</div>
<table class="summary-of-findings framed">
<tbody>
<tr class="table-header separated">
<td align="left" valign="top" colspan="7" rowspan="1" class="table-header"> <p><b> Pilocarpine compared to no treatment/placebo for preventing salivary gland dysfunction following radiotherapy</b> </p> </td> </tr>
<tr class="separated">
<td align="left" valign="top" colspan="7" rowspan="1" bgcolor="#ffffff"> <p><b>Patient or population:</b> patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region<br><b>Intervention:</b> pilocarpine<br><b>Comparison:</b> no treatment/placebo </p> </td> </tr>
<tr class="table-header separated">
<td align="left" valign="top" colspan="1" rowspan="2" class="table-header"> <p><b>Outcomes</b> </p> </td> <td align="left" valign="top" colspan="2" rowspan="1" class="table-tint table-highlight"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" valign="top" colspan="1" rowspan="2" class="table-header"> <p><b>Relative effect<br> (95% CI)</b> </p> </td> <td align="left" valign="top" colspan="1" rowspan="2" class="table-header"> <p><b>Number of participants<br> (studies)</b> </p> </td> <td align="left" valign="top" colspan="1" rowspan="2" class="table-header"> <p><b>Quality of the evidence<br> (GRADE)</b> </p> </td> <td align="left" valign="top" colspan="1" rowspan="2" class="table-header"> <p><b>Comments</b> </p> </td> </tr>
<tr class="table-header separated">
<td align="left" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>Risk with no treatment/placebo</b> </p> </td> <td align="left" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>Risk with pilocarpine</b> </p> </td> </tr>
<tr class="separated">
<td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Xerostomia â Up to and including 6 months postRT</p> <p>Studies used different ways of measuring the outcome and therefore we combined the studies using SMD </p> </td> <td align="left" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>â</p> </td> <td align="left" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>SMD 0.35 lower<br> (1.04 lower to 0.33 higher) </p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>â</p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>126<br> (2 RCTs) </p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>ââââ<br> VERY LOW<sup>1</sup></p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Insufficient evidence of a difference at this time point and also at the end of RT and 3 months postRT </p> <p>1 of the 2 studies in this assessment showed inconsistent results when using an alternative way of measuring this outcome at the 6âmonth time point. 2 further studies showed insufficient evidence of a difference, 1 at the end of RT and the other at 3 months postRT </p> </td> </tr>
<tr class="separated">
<td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Salivary flow rate (unstimulated) â Up to and including 3 months postRT</p> <p>Studies used different ways of measuring the outcome and therefore we combined the studies using SMD </p> </td> <td align="left" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>â</p> </td> <td align="left" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>MD 0.06 lower (0.23 lower to 0.11 higher)</p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>â</p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>24<br> (1 RCT) </p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>ââââ<br> VERY LOW<sup>2</sup></p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Insufficient evidence of a difference at this time point and also at the end of RT</p> <p>Same results for stimulated salivary flow rates at end of RT, and 3, 6 and 12 months postRT </p> <p>Same results for a further study at the end of RT and 3 months postRT looking at whether or not stimulated and unstimulated salivary flow was &gt; 0 g </p> </td> </tr>
<tr class="separated">
<td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Overall survival â Up to and including 6 months postRT</p> </td> <td align="left" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>724 per 1000</p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>775 per 1000<br> (579 to 1000) </p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>RR 1.07<br> (0.80 to 1.43) </p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>60<br> (1 RCT) </p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>ââââ<br> VERY LOW<sup>3</sup></p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Insufficient evidence of a difference</p> </td> </tr>
<tr class="separated">
<td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Quality of life â Up to and including 6 months postRT</p> <p>McMaster University Head and Neck Questionnaire (HNRQ). Score 1â7, lower score = poorer quality of life </p> </td> <td align="left" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>Control group mean was 5.3</p> </td> <td align="left" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>MD 0.20 higher<br> (0.19 lower to 0.59 higher) </p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>â</p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>90<br> (1 RCT) </p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>ââââ<br> VERY LOW<sup>3</sup></p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Insufficient evidence of a difference at this time point and also at the end of RT and 3 months postRT </p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Adverse effects</p> </td> <td align="" valign="" colspan="6" rowspan="1" class="table-tint table-highlight"> <p>Insufficient evidence of a difference between groups for any reported adverse event, apart from for sweating where data from 5 studies showed an increased risk associated with pilocarpine (RR 2.98, 95% CI 1.43 to 6.22; P = 0.004; I<sup>2</sup> = 0%; 389 participants; ââââ LOW<sup>4</sup>) </p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="7" rowspan="1" bgcolor="#ffffff"> <p>*The risk in the intervention group (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI)<br><br><b>CI:</b> confidence interval; <b>MD:</b> mean difference; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio; <b>SMD:</b> standardised mean difference; <b>RT:</b> radiotherapy </p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="7" rowspan="1" bgcolor="#ffffff"> <p><b>GRADE Working Group grades of evidence</b> <br><b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect<br><b>Moderate quality:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br><b>Low quality:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect<br><b>Very low quality:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr>
</tbody>
<tfoot><tr>
<td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded by 1 level for risk of bias, 1 level for imprecision (small sample size and 95% CIs include both possibility of benefit and harm), and 1 level for inconsistency (I<sup>2</sup> = 68%).<br><sup>2</sup>Downgraded by 1 level for risk of bias, and 2 levels for imprecision (single study with 12 participants per group and 95% CIs include both possibility of benefit and harm).<br><sup>3</sup>Downgraded by 1 level for risk of bias, and 2 levels for imprecision (single study and 95% CIs include both possibility of benefit and harm).<br><sup>4</sup>Downgraded by 1 level for risk of bias, and 1 level for imprecision (very wide 95% CIs). </p> </div> </td> </tr></tfoot>
</table>
</div> <div class="table" id="CD012744-tbl-0002"> <a href="#0" class="open-table-viewer open-in-figure-viewer">Open in table viewer</a><div class="table-heading">
<span class="table-label">Summary of findings 2.</span>Â <span class="table-title">Amifostine compared to no treatment/placebo for preventing salivary gland dysfunction following radiotherapy</span>
</div>
<table class="summary-of-findings framed">
<tbody>
<tr class="table-header separated">
<td align="left" valign="top" colspan="7" rowspan="1" class="table-header"> <p><b> Amifostine compared to no treatment/placebo for preventing salivary gland dysfunction following radiotherapy</b> </p> </td> </tr>
<tr class="separated">
<td align="left" valign="top" colspan="7" rowspan="1" bgcolor="#ffffff"> <p><b>Patient or population:</b> patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region<br><b>Intervention:</b> amifostine<br><b>Comparison:</b> no treatment/placebo </p> </td> </tr>
<tr class="table-header separated">
<td align="left" valign="top" colspan="1" rowspan="2" class="table-header"> <p><b>Outcomes</b> </p> </td> <td align="left" valign="top" colspan="2" rowspan="1" class="table-tint table-highlight"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" valign="top" colspan="1" rowspan="2" class="table-header"> <p><b>Relative effect<br> (95% CI)</b> </p> </td> <td align="left" valign="top" colspan="1" rowspan="2" class="table-header"> <p><b>Number of participants<br> (studies)</b> </p> </td> <td align="left" valign="top" colspan="1" rowspan="2" class="table-header"> <p><b>Quality of the evidence<br> (GRADE)</b> </p> </td> <td align="left" valign="top" colspan="1" rowspan="2" class="table-header"> <p><b>Comments</b> </p> </td> </tr>
<tr class="table-header separated">
<td align="left" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>Risk with no treatment/placebo</b> </p> </td> <td align="left" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>Risk with amifostine</b> </p> </td> </tr>
<tr class="separated">
<td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Xerostomia (0â4 scale â grade 2 or above) â 12 months postRT</p> </td> <td align="left" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>418 per 1000</p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>292 per 1000<br> (167 to 514) </p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>RR 0.70<br> (0.40 to 1.23) </p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>682<br> (7 studies) </p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>ââââ<br> LOW<sup>1</sup></p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Insufficient evidence of a difference at this time point. However, both at the end of RT (RR 0.35, 95% CI 0.19 to 0.67; 3 studies, 119 participants) and up to 3 months postRT (RR 0.66, 95% CI 0.48 to 0.92; 5 studies, 687 participants), amifostine reduced the risk of developing grade â¥ 2 xerostomia </p> </td> </tr>
<tr class="separated">
<td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Salivary flow rate (mg/5 min) (unstimulated) â 12 months postRT</p> </td> <td align="left" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>Control group mean was 0.16</p> </td> <td align="left" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>MD 0.32 higher<br> (0.09 higher to 0.55 higher) </p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>â</p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>27<br> (1 study) </p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>ââââ<br> VERY LOW<sup>2</sup></p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Amifostine led to increased unstimulated saliva flow both at 12 months postRT and at the end of RT, but there was insufficient evidence of a difference at 3 months postRT. This evidence was supported by a further study showing a benefit for amifostine at 12 months postRT when looking at incidence of producing &gt; 0.1 g of saliva over 5 minutes (RR 1.45, 95% CI 1.13 to 1.86; 175 participants). A further study narratively reported no difference </p> <p>Insufficient evidence of a difference in stimulated saliva flow at any time point</p> </td> </tr>
<tr class="separated">
<td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Overall survival at 12 to 24 months postRT</p> </td> <td align="left" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>450 per 1000**</p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>531 per 1000<br> (383 to 747) </p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>HR 1.18<br> (0.85 to 1.66) </p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>271<br> (2 studies) </p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>ââââ<br> VERY LOW<sup>3</sup></p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Insufficient evidence to determine whether or not amifostine reduces overall survival, progressionâfree survival, diseaseâfree survival or locoregional tumour control up to 24 months postRT </p> </td> </tr>
<tr class="separated">
<td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Quality of life (Patient Benefit Questionnaire) â 12 months postRT</p> <p>8 items each on a 10âpoint scale where higher = better QoL</p> </td> <td align="left" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>Control group mean was 6.66</p> </td> <td align="left" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>MD 0.7 higher<br> (0.2 higher to 1.2 higher) </p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>â</p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>180<br> (1 study) </p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>ââââ<br> VERY LOW<sup>2</sup></p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Amifostine led to a small improvement in quality of life at 12 months postRT, but there was insufficient evidence of a difference at the end of RT and 3 months postRT </p> <p>A further study narratively reported no difference at end of RT and 6, 12, 18, and 24 months postRT </p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Adverse effects</p> </td> <td align="" valign="" colspan="6" rowspan="1" class="table-tint table-highlight"> <p> </p>
<ul id="CD012744-list-0001">
<li> <p>Data from 5 studies showed an increased risk of vomiting associated with amifostine (RR 4.90, 95% CI 2.87 to 8.38; 601 participants; ââââ LOW<sup>4</sup>) </p> </li> <li> <p>Data from 3 studies showed an increased risk of hypotension associated with amifostine (RR 9.20, 95% CI 2.84 to 29.83; 376 participants; ââââ LOW<sup>4</sup>) </p> </li> <li> <p>Data from 4 studies showed an increased risk of nausea associated with amifostine (RR 2.60, 95% CI 1.81 to 3.74; 556 participants; ââââ LOW<sup>4</sup>) </p> </li> <li> <p>Data from 3 studies showed an increased risk of allergic response associated with amifostine (RR 7.51, 95% CI 1.40 to 40.39; 524 participants; ââââ LOW<sup>4</sup>) </p> </li> </ul>
<p></p> <p>There was insufficient evidence of a difference between groups for any other adverse events </p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="7" rowspan="1" bgcolor="#ffffff"> <p>*The risk in the intervention group (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI)<br> **2014 5âyear overall survival rate of patients with head and neck squamous cell carcinoma (<a href="http://www.who.int/selection_medicines/committees/expert/20/applications/HeadNeck.pdf" target="_blank" class="external">www.who.int/selection_medicines/committees/expert/20/applications/HeadNeck.pdf</a>)<br><br><b>CI:</b> confidence interval; <b>HR:</b> hazard ratio; <b>MD:</b> mean difference; <b>QoL:</b> quality of life; <b>RR:</b> risk ratio; <b>RT:</b> radiotherapy </p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="7" rowspan="1" bgcolor="#ffffff"> <p><b>GRADE Working Group grades of evidence</b> <br><b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect<br><b>Moderate quality:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br><b>Low quality:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect<br><b>Very low quality:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr>
</tbody>
<tfoot><tr>
<td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded by 1 level for risk of bias, and 1 level for inconsistency (I<sup>2</sup> = 83%).<br><sup>2</sup>Downgraded by 1 level for risk of bias, and 2 levels for imprecision (single study and small sample size).<br><sup>3</sup>Downgraded by 1 level for risk of bias, and 2 levels for imprecision (small sample size and 95% CIs include both possibility of benefit and harm).<br><sup>4</sup>Downgraded by 1 level for risk of bias, and 1 level for imprecision (very wide 95% CIs). </p> </div> </td> </tr></tfoot>
</table>
</div> <div class="table" id="CD012744-tbl-0003"> <a href="#0" class="open-table-viewer open-in-figure-viewer">Open in table viewer</a><div class="table-heading">
<span class="table-label">Summary of findings 3.</span>Â <span class="table-title">Palifermin compared to placebo for preventing salivary gland dysfunction following radiotherapy</span>
</div>
<table class="summary-of-findings framed">
<tbody>
<tr class="table-header separated">
<td align="left" valign="top" colspan="7" rowspan="1" class="table-header"> <p><b> Palifermin compared to placebo for preventing salivary gland dysfunction following radiotherapy</b> </p> </td> </tr>
<tr class="separated">
<td align="left" valign="top" colspan="7" rowspan="1" bgcolor="#ffffff"> <p><b>Patient or population:</b> patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region<br><b>Intervention:</b> palifermin<br><b>Comparison:</b> placebo </p> </td> </tr>
<tr class="table-header separated">
<td align="left" valign="top" colspan="1" rowspan="2" class="table-header"> <p><b>Outcomes</b> </p> </td> <td align="left" valign="top" colspan="2" rowspan="1" class="table-tint table-highlight"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" valign="top" colspan="1" rowspan="2" class="table-header"> <p><b>Relative effect<br> (95% CI)</b> </p> </td> <td align="left" valign="top" colspan="1" rowspan="2" class="table-header"> <p><b>Number of participants<br> (studies)</b> </p> </td> <td align="left" valign="top" colspan="1" rowspan="2" class="table-header"> <p><b>Quality of the evidence<br> (GRADE)</b> </p> </td> <td align="left" valign="top" colspan="1" rowspan="2" class="table-header"> <p><b>Comments</b> </p> </td> </tr>
<tr class="table-header separated">
<td align="left" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>Risk with placebo</b> </p> </td> <td align="left" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>Risk with palifermin</b> </p> </td> </tr>
<tr class="separated">
<td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Xerostomia (0â4 scale â grade 2 or above) â Up to and including 3 months postRT</p> </td> <td align="left" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>727 per 1000</p> </td> <td align="" valign="" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>705 per 1000<br> (560 to 887) </p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>RR 0.97<br> (0.77 to 1.22) </p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>471<br> (3 studies) </p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>ââââ<br> LOW<sup>1</sup></p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Insufficient evidence of a difference at this time point</p> </td> </tr>
<tr class="separated">
<td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Overall survival at 42 to 72 months from baseline</p> </td> <td align="left" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>450 per 1000**</p> </td> <td align="" valign="" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>450 per 1000<br> (324 to 626) </p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>HR 1.00<br> (0.72 to 1.39) </p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>(3 studies)</p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>ââââ<br> MODERATE<sup>2</sup></p> </td> <td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Insufficient evidence to determine whether or not amifostine reduces overall survival and progressionâfree survival up to 72 months </p> </td> </tr>
<tr class="separated">
<td align="left" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Adverse effects</p> </td> <td align="left" valign="top" colspan="6" rowspan="1" class="table-tint table-highlight"> <p>There was insufficient evidence of patients in either group experiencing more or less adverse events </p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="7" rowspan="1" bgcolor="#ffffff"> <p>*The risk in the intervention group (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI) </p> <p>**2014 5âyear overall survival rate of patients with head and neck squamous cell carcinoma (<a href="http://www.who.int/selection_medicines/committees/expert/20/applications/HeadNeck.pdf" target="_blank" class="external">www.who.int/selection_medicines/committees/expert/20/applications/HeadNeck.pdf</a>)<br><br><b>CI:</b> confidence interval; <b>HR:</b> hazard ratio; <b>RR:</b> risk ratio; <b>RT:</b> radiotherapy </p> </td> </tr>
<tr class="separated">
<td align="" valign="" colspan="7" rowspan="1" bgcolor="#ffffff"> <p><b>GRADE Working Group grades of evidence</b> <br><b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect<br><b>Moderate quality:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br><b>Low quality:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect<br><b>Very low quality:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr>
</tbody>
<tfoot><tr>
<td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded by 1 level for imprecision (95% CIs include both possibility of benefit and harm), and 1 level for inconsistency (I<sup>2</sup> = 76%).<br><sup>2</sup>Downgraded by 1 level for imprecision (95% CIs include both possibility of benefit and harm). </p> </div> </td> </tr></tfoot>
</table>
</div> </section></section></body></html></body></html>
